Biogen Idec Inc. and Elan Corp. warned doctors of the possibility of serious liver injury in patients being treated with the multiple-sclerosis drug Tysabri. The new warning, in a letter posted on the Food and Drug Administration’s Web site, was recently included in prescribing information for Tysabri use in patients with Crohn’s disease, a chronic, progressive disease marked by inflammation of the bowel. Last month, the FDA approved Tysabri for Crohn’s patients who have failed other treatments, including Johnson & Johnson’s Remicade and Abbott Laboratories’ Humira, although the drug hasn’t yet been launched as a treatment for Crohn’s.
